Genprex (GNPX)

Executive Summary

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on oncology and diabetes. Its lead candidate, REQORSA™ (quaratusugene ozeplasmid), uses the proprietary Oncoprex® non-viral delivery system to restore tumor suppressor gene TUSC2. REQORSA is currently in two Phase 1/2 trials: one combining with osimertinib and platinum-based chemotherapy in first-line non-small cell lung cancer (NSCLC; NCT04486833, recruiting, estimated completion 2029) and another combining with atezolizumab in extensive-stage small cell lung cancer (SCLC; NCT05703971, recruiting, estimated completion 2027). A third trial (NCT05062980) combining REQORSA with pembrolizumab, docetaxel, and ramucirumab in NSCLC was terminated in February 2025. Genprex also has a preclinical diabetes program (GPX-002) aiming to deliver a gene to convert alpha cells into insulin-producing cells. The company's near-term value is heavily dependent on clinical data from its lung cancer trials and advancement of its diabetes pipeline.

Upcoming Catalysts (preview)

• H2 2026Interim data from Phase 1/2 REQORSA + osimertinib/chemo in NSCLC40% success
• 2027Initial safety/efficacy data from Phase 1/2 REQORSA + atezolizumab in SCLC35% success
• 2027IND filing or preclinical update for GPX-002 diabetes gene therapy25% success